Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20674553 | 0.78 | GLO1 (0.54) | MEN1KMT2AALOX15TDP1NPC1 | |
| SCHEMBL20674177 | 0.76 | KDM4E (0.41) | ALDH1A1LMNASMN1; SMN2ELANE | |
| SCHEMBL20674166 | 0.74 | KMT2A (0.47) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL20674488 | 0.73 | ADORA3 (0.44) | MEN1KMT2AATMSLC40A1TP53 | |
| SCHEMBL20674176 | 0.72 | PARP1 (0.54) | NPC1RAB9AALDH1A1HPGDLMNA | |
| SCHEMBL20674512 | 0.72 | HTT (0.46) | MEN1KMT2ATP53ALOX15TDP1 | |
| SCHEMBL23937888 | 0.71 | GLO1 (0.41) | SLC40A1ALOX15TDP1POLBALDH1A1 | |
| SCHEMBL20674535 | 0.71 | KDM4E (0.50) | KMT2AALOX15TDP1RAB9AALDH1A1 | |
| SCHEMBL29918706 | 0.71 | TDP1 (0.71) | MEN1KMT2ASLC40A1TP53TDP1 | |
| SCHEMBL5053488 | 0.71 | TDP1 (0.71) | MEN1KMT2ASLC40A1TP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | MEN1 3422/4885KMT2A 2411/4885ATM 1154/4885 |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | MEN1 3396/4885KMT2A 2302/4885ATM 1094/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | MEN1 3422/4885KMT2A 2411/4885ATM 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.